T2 Biosystems, which is developing diagnostics tests that screen for sepsis and hemostasis, filed on Wednesday with the SEC to raise up to $69 million in an initial public offering. The company claims that its technology platform will lead to an earlier detection of sepsis, which is the most expensive hospital-treated condition in the US with a 30% mortality rate. Combined with the detection of impaired hemostasis, T2 pegs its annual US addressable market at $3 billion. Primary backers include Goldman Sachs ( GS ), Polaris Partners and Flagship Ventures.
Help employers find you! Check out all the jobs and post your resume.
